Condition: Hepatocellular Carcinoma · Sponsor: Lion TCR Pte. Ltd.
This is a single center and open-label study to determine the safety and efficacy of mRNA HBV-TCR redirected T-cells in HBV-related HCC who are not amenable to/failed conventional treatment.
This description comes directly from the study's public registry record.
Wang Zhe · +86 15902091916 · zhe.wang@liontcr.com
Always discuss trial participation with your own doctor first.
| Gaobo Boren Hospital | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06961617